FLT3 Mutations in Refractory and Relapsed AML: Clonal Evolution, Resistance Mechanisms and Implications for Targeted Therapy
Acute myeloid leukemia (AML) is an aggressive disease with poor outcomes, and despite initial responses to chemotherapy, most patients eventually relapse.
Learn about the importance of FLT3 mutations in refractory and relapsed AML by downloading our infographic.
FLT3 Mutations in Refractory and Relapsed AML: Clonal Evolution, Resistance Mechanisms and Implications for Targeted Therapy
Supported by unrestricted educational funding from Astellas.
